NewEdge Wealth LLC Has $3.19 Million Stake in HCA Healthcare, Inc. $HCA

NewEdge Wealth LLC lessened its stake in HCA Healthcare, Inc. (NYSE:HCA) by 24.6% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,747 shares of the company’s stock after selling 2,196 shares during the quarter. NewEdge Wealth LLC’s holdings in HCA Healthcare were worth $3,193,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of HCA. Nomura Asset Management Co. Ltd. lifted its position in shares of HCA Healthcare by 6.2% during the 4th quarter. Nomura Asset Management Co. Ltd. now owns 64,237 shares of the company’s stock worth $29,990,000 after buying an additional 3,724 shares in the last quarter. Advisors Capital Management LLC increased its position in shares of HCA Healthcare by 61.5% during the fourth quarter. Advisors Capital Management LLC now owns 6,836 shares of the company’s stock valued at $3,192,000 after acquiring an additional 2,604 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its position in HCA Healthcare by 11.9% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 2,311,112 shares of the company’s stock worth $1,078,966,000 after purchasing an additional 245,887 shares during the last quarter. Liberty Wealth Management LLC purchased a new stake in shares of HCA Healthcare during the 4th quarter valued at $1,905,000. Finally, Intech Investment Management LLC boosted its holdings in shares of HCA Healthcare by 10.0% in the 4th quarter. Intech Investment Management LLC now owns 55,273 shares of the company’s stock worth $25,805,000 after buying an additional 5,019 shares during the last quarter. 62.73% of the stock is currently owned by institutional investors.

HCA Healthcare Stock Up 1.5%

Shares of HCA stock opened at $382.28 on Friday. The firm has a market cap of $84.80 billion, a P/E ratio of 13.15, a price-to-earnings-growth ratio of 1.27 and a beta of 1.12. The business has a 50-day moving average price of $386.95 and a two-hundred day moving average price of $453.73. HCA Healthcare, Inc. has a 12-month low of $330.00 and a 12-month high of $556.52.

HCA Healthcare (NYSE:HCA) last released its earnings results on Friday, July 24th. The company reported $7.59 earnings per share for the quarter, beating analysts’ consensus estimates of $7.56 by $0.03. HCA Healthcare had a negative return on equity of 295.93% and a net margin of 8.89%.The company had revenue of $20.23 billion during the quarter, compared to analyst estimates of $19.76 billion. During the same quarter in the previous year, the company posted $6.84 EPS. HCA Healthcare’s revenue for the quarter was up 8.7% on a year-over-year basis. As a group, research analysts expect that HCA Healthcare, Inc. will post 29.19 EPS for the current fiscal year.

HCA Healthcare News Roundup

Here are the key news stories impacting HCA Healthcare this week:

• Positive Sentiment: HCA beat Q2 earnings estimates, reporting $7.59 per share versus expectations around $7.56-$7.57, while revenue rose 8.7% year over year to $20.23 billion and also topped estimates. HCA Healthcare earnings report
• Positive Sentiment: Management cited strong admissions and higher revenue per admission as key drivers of the quarter, suggesting healthy demand trends across its hospital network. Zacks article on HCA Q2 results
• Neutral Sentiment: HCA said its updated guidance is consistent with its earlier preview, so the quarter appears to confirm previously signaled results rather than deliver a major surprise. BusinessWire Q2 results
• Negative Sentiment: The company trimmed parts of its 2026 outlook, pointing to higher expenses and weaker surgical volumes as headwinds that could limit margin expansion. Zacks guidance revision article
• Negative Sentiment: Separate investor-law-firm investigations into HCA may add some legal overhang, though these notices are not operational results. Pomerantz investor alert

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Cantor Fitzgerald lowered their price objective on shares of HCA Healthcare from $588.00 to $525.00 and set an “overweight” rating on the stock in a research report on Tuesday, July 7th. Weiss Ratings downgraded HCA Healthcare from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, June 9th. Sanford C. Bernstein reissued a “market perform” rating on shares of HCA Healthcare in a research report on Wednesday, July 15th. Oppenheimer cut their price target on HCA Healthcare from $540.00 to $520.00 and set an “outperform” rating for the company in a research note on Monday, April 27th. Finally, Leerink Partners dropped their price objective on shares of HCA Healthcare from $573.00 to $500.00 and set an “outperform” rating on the stock in a report on Monday, April 27th. Fourteen analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $483.45.

HCA Healthcare Company Profile

HCA Healthcare is a for?profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.

The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.